Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology firm, have announced a collaboration to enhance cancer diagnostics and treatment in Turkey and nearby regions. This partnership leverages Genoks' genomics expertise and Velsera's innovative Clinical Genomics Workspace (CGW) platform for comprehensive data analysis of solid tissue, liquid tumor, and hematological cancer samples. By integrating CGW, Genoks aims to improve its cancer diagnostic services, offering precise insights to guide treatment decisions and enhance patient outcomes. Dr. Yunus Alp, MD Clinical Geneticist of Genoks, expressed excitement about the partnership's potential to revolutionize cancer care in the region.
The Clinical Genomics Workspace is tailored for oncology and inherited disease specialists, aiding in the growth of Next-Generation Sequencing (NGS) testing programs. This collaboration underscores the importance of strategic partnerships in advancing cancer research and patient care. By combining their strengths, Genoks and Velsera are poised to make a significant impact in oncology, providing state-of-the-art testing solutions and personalized cancer care. This partnership highlights their shared commitment to innovation and excellence, aiming to transform cancer diagnostics and treatment in Turkey and beyond.
Comments
Post a Comment